Tuesday, May 15, 2018

Valeant upped to buy by Mizuho

Mizuho Securities upgraded Valeant Pharmaceuticals (NYSE: VRX) from Neutral to Buy with a price target of $27.00 (from $15.00), ‘acknowledge turnaround.’
at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.